EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

MXene-Polydopamine-antiCEACAM1 Antibody Complex as a Strategy for Targeted Ablation of Melanoma

Anastasia Konieva, Volodymyr Deineka iD, Kateryna Diedkova, Daniel Aguilar-Ferrer, Mykola Lyndin iD, Gunther Wennemuth, Viktoriia Korniienko, Sergiy Kyrylenko iD, Alexey Lihachev, Veronika Zahorodna iD, Ivan Baginskiy iD, Emerson Coy iD and 6 more

ACS Applied Materials & Interfaces · 2024

DOI: 10.1021/acsami.4c08129 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2024. Written by Anastasia Konieva and 17 co-authors. Institution: Department of Anatomy, University Hospital Essen, Hufelandstraße 55, 45147 Essen, Germany. Major MEDLINE topics: Polymers, Indoles, Melanoma. Cited 36 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Narodowe Centrum Nauki, HORIZON EUROPE Marie Sklodowska-Curie Actions, Latvijas Zinatnes Padome.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Photothermal therapy (PTT) is a method for eradicating tumor tissues through the use of photothermal materials and photosensitizing agents that absorb light energy from laser sources and convert it into heat, which selectively targets and destroys cancer cells while sparing healthy tissue. MXenes have been intensively investigated as photosensitizing agents for PTT. However, achieving the selectivity of MXenes to the tumor cells remains a challenge. Specific antibodies (Ab) against tumor antigens can achieve homing of the photosensitizing agents toward tumor cells, but their immobilization on MXene received little attention. Here, we offer a strategy for the selective ablation of melanoma cells using MXene-polydopamine-antiCEACAM1 Ab complexes. We coated Ti3C2Tx MXene with polydopamine (PDA), a natural compound that attaches Ab to the MXene surface, followed by conjugation with an anti-CEACAM1 Ab. Our experiments confirm the biocompatibility of the Ti3C2Tx-PDA and Ti3C2Tx-PDA-antiCEACAM1 Ab complexes across various cell types. We also established a protocol for the selective ablation of CEACAM1-positive melanoma cells using near-infrared irradiation. The obtained complexes exhibit high selectivity and efficiency in targeting and eliminating CEACAM1-positive melanoma cells while sparing CEACAM1-negative cells. These results demonstrate the potential of MXene-PDA-Ab complexes for cancer therapy. They underline the critical role of targeted therapies in oncology, offering a promising avenue for the precise and safe treatment of melanoma and possibly other cancers characterized by specific biomarkers. Future research will aim to refine these complexes for clinical use, paving the way for new strategies for cancer treatment.

Subjects

MeSH terms (MEDLINE)

PolymersIndolesMelanomaHumansCell Line, TumorPhotosensitizing AgentsTitaniumAnimalsMiceCarcinoembryonic AntigenPhotothermal Therapy

Author keywords

CEACAM1MXeneantibody immobilizationanticancer therapyphotothermal ablationtargeted delivery

Substances

polydopaminePolymersIndolesPhotosensitizing AgentsTitaniumCarcinoembryonic Antigentitanium carbide

Authors and institutions

  • Department of Anatomy, University Hospital Essen, Hufelandstraße 55, 45147 Essen, Germany.
  • Biomedical Research Center, Medical Institute, Sumy State University, 31 Sanatornaya Str., 40018 Sumy, Ukraine.
  • Insitute of Atomic Physics and Spectroscopy, University of Latvia, 3 Jelgavas Str., LV-1004 Riga, Latvia.
  • NanoBioMedical Centre, Adam Mickiewicz University, 3, Wszechnicy Piastowskiej Str., 61-614 Poznan, Poland.
  • Institut Europeen des Membranes, IEM, UMR 5635, Université de Montpellier, ENSCM, CNRS, 34730 Montpellier, France.
  • Materials Research Centre, 3 Krzhizhanovskogo Str., 03142 Kyiv, Ukraine.

ORCID profiles: Volodymyr Deineka, Mykola Lyndin, Sergiy Kyrylenko, Veronika Zahorodna, Ivan Baginskiy, Emerson Coy, Wojciech Simka, Maksym Pogorielov

Funding

  • Narodowe Centrum Nauki
  • HORIZON EUROPE Marie Sklodowska-Curie Actions
  • Latvijas Zinatnes Padome
  • French Government Scholarship

Cite

APA

Konieva, A., Deineka, V., Diedkova, K., Aguilar-Ferrer, D., Lyndin, M., Wennemuth, G., Korniienko, V., Kyrylenko, S., Lihachev, A., Zahorodna, V., Baginskiy, I., Coy, E., Gogotsi, O., Blacha-Grzechnik, A., Simka, W., Kube-Golovin, I., Iatsunskyi, I., & Pogorielov, M. (2024). MXene-Polydopamine-antiCEACAM1 Antibody Complex as a Strategy for Targeted Ablation of Melanoma. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c08129

Vancouver

Konieva A, Deineka V, Diedkova K, Aguilar-Ferrer D, Lyndin M, Wennemuth G, et al. MXene-Polydopamine-antiCEACAM1 Antibody Complex as a Strategy for Targeted Ablation of Melanoma. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c08129

BibTeX
@article{Konieva2024,
  author = {Konieva, Anastasia and Deineka, Volodymyr and Diedkova, Kateryna and Aguilar-Ferrer, Daniel and Lyndin, Mykola and Wennemuth, Gunther and Korniienko, Viktoriia and Kyrylenko, Sergiy and Lihachev, Alexey and Zahorodna, Veronika and Baginskiy, Ivan and Coy, Emerson and Gogotsi, Oleksiy and Blacha-Grzechnik, Agata and Simka, Wojciech and Kube-Golovin, Irina and Iatsunskyi, Igor and Pogorielov, Maksym},
  title = {MXene-Polydopamine-antiCEACAM1 Antibody Complex as a Strategy for Targeted Ablation of Melanoma},
  journal = {ACS Applied Materials & Interfaces},
  year = {2024},
  doi = {10.1021/acsami.4c08129}
}
Start for free →